Quick Answer
Editas Medicine, Inc. reported Total Assets of $186.53 million for the year ending 2025.
- Editas Medicine, Inc. showed a decrease of -45.4% in Total Assets from 2024 to 2025.
- This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $248.81 million | Q2 2016: $249.60 million | Q3 2016: $242.15 million | Q1 2017: $395.04 million | Q2 2017: $368.85 million | Q3 2017: $339.13 million | Q1 2018: $403.98 million | Q2 2018: $393.53 million | Q3 2018: $387.63 million | Q1 2019: $378.92 million | Q2 2019: $355.63 million | Q3 2019: $372.36 million | Q1 2020: $466.74 million | Q2 2020: $655.48 million | Q3 2020: $597.16 million | Q1 2021: $780.29 million | Q2 2021: $755.88 million | Q3 2021: $717.02 million | Q1 2022: $623.11 million | Q2 2022: $580.83 million | Q3 2022: $531.03 million | Q1 2023: $464.11 million | Q2 2023: $541.95 million | Q3 2023: $504.65 million | Q1 2024: $440.35 million | Q2 2024: $384.80 million | Q3 2024: $327.57 million | Q1 2025: $263.65 million | Q2 2025: $210.58 million | Q3 2025: $201.75 million.
- Over the full 11 years of available data (2015 to 2025), Editas Medicine, Inc.'s Total Assets has grown by 24.9%.
- Historical annual values: Fiscal year 2025: $186.53 million | Fiscal year 2024: $341.59 million | Fiscal year 2023: $499.15 million | Fiscal year 2022: $514.32 million | Fiscal year 2021: $677.48 million | Fiscal year 2020: $572.60 million | Fiscal year 2019: $508.89 million | Fiscal year 2018: $420.39 million | Fiscal year 2017: $373.26 million | Fiscal year 2016: $229.18 million | Fiscal year 2015: $149.36 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: